SCHEMBL13041384

SCHEMBL13041384

COc1ccc(Cn2c(=O)c(-c3nc4ccccc4n3S(=O)(=O)C(F)(F)F)c(OS(=O)(=O)C(F)(F)F)c3cc(Cl)ccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.45
SMN1; SMN2 Q16637 5/20 0.42
HTT P42858 4/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CNR2 P34972 1/20 0.42
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
P2RX4 Q99571 1/20 0.40
TBXA2R P21731 2/20 0.40
GAA P10253 2/20 0.40
KMT2A Q03164 1/20 0.40
NTRK1 P04629 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPC1 O15118 1/20 0.39
GLA P06280 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041381 0.90 TP53 (0.48) TP53SMN1; SMN2HTTALDH1A1KDM4E
SCHEMBL13078050 0.88 TP53 (0.47) TP53SMN1; SMN2HTTALDH1A1KDM4E
SCHEMBL13622543 0.80 HTT (0.43) TP53SMN1; SMN2HTTALDH1A1KDM4E
SCHEMBL6086148 0.75 ALDH1A1 (0.52) HTTALDH1A1KDM4ELMNAMAPT
SCHEMBL13041323 0.75 KDR (0.36) SMN1; SMN2ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL20313096 0.75 BRD4 (0.40) SMN1; SMN2ALDH1A1KDM4ELMNAMAPT
SCHEMBL4844385 0.73 CSF1R (0.42) SMN1; SMN2ALDH1A1KDM4ELMNAHPGD
SCHEMBL17457424 0.73 BRD4 (0.41) SMN1; SMN2ALDH1A1KDM4EHPGDTDP1
SCHEMBL20313085 0.73 MAPT (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTHPGD
SCHEMBL29859802 0.72 ERCC5 (0.39) ALDH1A1MAPTGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573079-A2 Benzimidazole quinolinones and uses thereof Novartis Vaccines and Diagnostics, Inc. (US) 2013-03-27 EP disclosed
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 US disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 TP53 2043/4885SMN1; SMN2 2956/4885HTT 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.